Nutraceuticals for the management of conditions related to type 2 diabetes

ABSTRACT

Disclosed are nutraceutical formulations, including extracts comprising the hydrophilic and lipophilic fractions of stabilized rice bran. Also disclosed are methods for using said nutraceutical formulations for the management or remediation of conditions related to type II diabetes in humans, including methods for decreasing HbA1c and fasting glucose blood concentrations, and for increasing serum fasting insulin levels.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/573,561 filed Sep. 19, 2019, which is a continuation-in-part of U.S.application Ser. No. 14/923,666, filed Oct. 27, 2015, now pending, whichis a continuation of U.S. application Ser. No. 13/494,998, filed Jun.13, 2012, now U.S. Pat. No. 9,192,180, which is a continuation-in-partof U.S. application Ser. No. 12/882,202, filed Sep. 15, 2010, now U.S.Pat. No. 8,945,642. The entire content of each of the applicationsmentioned in this paragraph are hereby incorporated by reference intheir entirety.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[Not Applicable]

TECHNICAL FIELD

The present invention relates to methods for the remediation of diseaseusing a nutritionally enhanced derivative (isolate) from Stabilized RiceBran (SRB) with improved yield characteristics.

BACKGROUND

Type II diabetes is a worldwide increasing health concern. According tothe World Health Organization, in 2008 the global prevalence wasestimated at 4.7% and by 2014 it had increased to 8.5%; some projectionsestimate a global prevalence between 9.8% and 11% by the year 2030.

There exist a need in the art to provide functional foods which help inthe prevention of diabetes. Among other things, the present disclosureprovides a nutraceutical formulation that actively participates in theremediation of early type II diabetes.

SUMMARY OF THE INVENTION

Provided are nutraceuticals and their use for the management of healthconditions associated with either the development or status of type IIdiabetes, said health conditions including for example levels of fastingglucose (FG), glycosylated hemoglobin (HbA1c), insulin, high densitylipoprotein (HDL), low density lipoprotein (LDL), total cholesterol andtriglycerides.

In one aspect, the disclosure provides nutraceuticals, and methods ofuse, that substantially lower glucose, HbA1c, total cholesterol and LDLin diabetics, and with people showing impaired glucose tolerance,characteristic of a pre-diabetic stage.

In a further aspect, the disclosure provides nutraceuticals, and methodsof use that increase insulin production, and reduce glucose levels, indiabetics with higher glucose levels and HbA1c values.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1E. A posteriori mean comparison tests for variables showingstatistically significant differences (p<0.05) between treatments in theG1 group of participants, according to the Kruskal-Wallis non parametricANOVA.

FIG. 2 . Percentage of participants falling within normal glucose valuesbefore and after the nutraceutical intervention in the 4 dose treatmentsof the nutraceutical for the G1 diabetic group.

FIG. 3 . Percentage of participants falling within normal HbA1c values(4.2%-6.2%) before and after the nutraceutical intervention in the 4dose treatments of the nutraceutical for the G1 diabetic group.

FIG. 4 . Percentage of participants falling with in normal range forinsulin values (2-27 μlU/ml) before and after the nutraceuticalintervention in the 4 dose treatments of the nutraceutical for the G1diabetic group.

FIG. 5 . Percentage of participants falling within normal of totalcholesterol values (40-200 mg/dl) before and after the nutraceuticalintervention in the 4 dose treatments of the nutraceutical for the G1diabetic group.

FIG. 6 . Percentage of participants falling within the normal range(30-70 mg/dl) for high density lipoproteins (HDL) before and after thenutraceutical intervention in the 4 dose treatments of the nutraceuticalfor the G1 diabetic group.

FIG. 7 . Percentage of participants falling within the normal range(70-170 mg/dl) for low density lipoproteins (LDL) before and after thenutraceutical intervention in the 4 dose treatments of the nutraceuticalfor the G1 diabetic group.

FIG. 8 . Percentage of participants falling within the normal range(0-160 mg/dl) for triglycerides (TRIG) before and after thenutraceutical intervention in the 4 dose treatments of the nutraceuticalfor the G1 diabetic group.

FIG. 9 . Percentage of participants falling within normal glucose valuesbefore and after the nutraceutical intervention in the 4 dose treatmentsof the nutraceutical for the G2 diabetic group.

FIG. 10 . Percentage of participants falling within normal HbA1c(4.2%-6.2%) values before and after the nutraceutical intervention inthe 4 dose treatments of the nutraceutical for the G2 diabetic group.

FIG. 11 . Percentage of participants falling within normal insulin (2-27μl U/ml) values before and after the nutraceutical intervention in the 4dose treatments of the nutraceutical for the G2 diabetic group.

FIG. 12 . Percentage of participants falling within normal of totalcholesterol values (40-200 mg/dl) before and after the nutraceuticalintervention in the 4 dose treatments of the nutraceutical for the G2diabetic group.

FIG. 13 . Percentage of participants falling within the normal range(30-70 mg/dl) for high density lipoproteins (HDL) before and after thenutraceutical intervention in the 4 dose treatments of the nutraceuticalfor the G2 diabetic group.

FIG. 14 . Percentage of participants falling within the normal range(70-170 mg/dl) for low density lipoproteins (LDL) before and after thenutraceutical intervention in the 4 dose treatments of the nutraceuticalfor the G2 diabetic group.

FIG. 15 . Percentage of participants falling within the normal range(0-160 mg/dl) for triglycerides (TRIO) before and after thenutraceutical intervention in the 4 dose treatments of the nutraceuticalfor the G2 diabetic group.

DETAILED DESCRIPTION

The Examples that follow are intended to be illustrative of the aspectsand embodiments described above. Neither the above disclosure nor theExamples below should be viewed as limiting to the scope of the appendedclaims. One of skill in the art will appreciate that the disclosure isnot limited by the particular terminology which is used to describe andillustrate the various aspects of the disclosure.

Presented herein is disclosure showing that nutraceutical formulations,comprising nutraceutical extract from the hydrophilic and lipophilicfractions of stabilized rice bran prepared in accordance with thepresent disclosure, and related regimens, have a positive impact on thestatus and progression of type II diabetes.

Disclosed are nutraceutical formulations, including extracts comprisinghydrophilic and lipophilic fractions of stabilized rice bran. Alsodisclosed are methods for using these nutraceutical formulations for themanagement or remediation of conditions related to type II diabetes inhumans.

There are presented herein methods for using nutraceuticals of thepresent disclosure for decreasing HbA1c blood concentrations, decreasingfasting glucose blood concentrations, and increasing serum fastinginsulin levels in type II diabetic and type II pre-diabetic patients.

There are presented nutraceutical formulations herein and methods ofusing these nutraceutical formulations to decrease fasting glucose (FG)concentrations in the blood of patients having HbA1c of ≥6.1% and <7.5.In certain instances, the decrease in fasting glucose (FG) bloodconcentrations in the blood of patients having HbA1c of ≥6.1% and <7.5comprises a 20 to 60 mg/dl drop in fasting glucose (FG) bloodconcentration, a 25 to 55 mg/dl drop in fasting glucose (FG) bloodconcentration, a 30 to 50 mg/dl drop in fasting glucose (FG) bloodconcentration; a 30 to 45 mg/dl drop in fasting glucose (FG) bloodconcentration, a 30 to 40 mg/dl drop in fasting glucose (FG) bloodconcentration; 35 to 50 mg/dl drop in fasting glucose (FG) bloodconcentration, a 35 to 45 mg/dl drop in fasting glucose (FG) bloodconcentration, or a 35 to 40 mg/dl drop in fasting glucose (FG) bloodconcentration.

There are also presented nutraceutical formulations herein and methodsof using these nutraceutical formulations to decrease HbA1c in the bloodof patients having HbA1c of >6.1% and <7.5. In certain instances, thedecrease in HbA1c in the blood of patients having HbA1c of >6.1% and<7.5 comprises a decrease of from 0.2% to 2.0%, from 0.5% to 2.0%, from0.5% to 1.5%, or from 0.5% to 1.0%. This decrease in HbA1c can beconcomitant with, or independent of the decrease in fasting glucose (FG)concentrations disclosed above for patients having HbA1c of >6.1% and<7.5.

There are also presented nutraceutical formulations herein and methodsof using these nutraceutical formulations to increase fasting seruminsulin levels of patients having HbA1c of >6.1% and <7.5. This increasein fasting serum insulin levels in patients having HbA1c of >6.1% and<7.5 results in fasting serum insulin levels of from 8 to 16 uIU/ml,from 9 to 15 uIU/ml, 10 to 14 uIU/ml, from 10 to 13 uIU/ml, from 10 to12 uIU/ml, or from 11 to 12 uIU/ml. This increase in fasting seruminsulin levels is concomitant with or independent of the decrease infasting glucose (FG) concentrations, and decrease in HbA1c discussedabove for patients having HbA1c of >6.1% and <7.5.

There are also presented nutraceutical formulations herein and methodsof using these nutraceutical formulations to decrease fasting glucose(FG) concentrations in the blood of patients having HbA1c≥7.5. Incertain instances, the decrease in fasting glucose (FG) bloodconcentrations in the blood of patients having HbA1c>7.5 comprises a 20to 60 mg/dl drop in fasting glucose (FG) blood concentration, a 25 to 55mg/dl drop in fasting glucose (FG) blood concentration, a 30 to 50 mg/dldrop in fasting glucose (FG) blood concentration; a 30 to 45 mg/dl dropin fasting glucose (FG) blood concentration, a 30 to 40 mg/dl drop infasting glucose (FG) blood concentration; 35 to 50 mg/dl drop in fastingglucose (FG) blood concentration, a 35 to 45 mg/dl drop in fastingglucose (FG) blood concentration, or a 35 to 40 mg/dl drop in fastingglucose (FG) blood concentration.

There are also presented nutraceutical formulations herein and methodsof using these nutraceutical formulations to decrease HbA1c in the bloodof patients having HbA1c of ≥7.5. In certain instances, the decrease inHbA1c in the blood of patients having HbA1c of ≥7.5 comprises a decreaseof from 0.2% to 2.0%, from 0.2% to 1.0%, from 0.2% to 0.5%, from 0.5% to2.0%, from 0.5% to 1.5%, or from 0.5% to 1.0%. This decrease in HbA1ccan be concomitant with, or independent of the decrease in fastingglucose (FG) concentrations disclosed above for patients having HbA1c of≥7.5.

There are also presented nutraceutical formulations herein and methodsof using these nutraceutical formulations to increase fasting seruminsulin levels of patients having HbA1c≥7.5. This increase in fastingserum insulin levels in patients having HbA1c of ≥7.5 results in fastingserum insulin levels of from 6 to 18 uIU/ml, from 7 to 17 uIU/ml, 8 to16 uIU/ml, from 10 to 15 uIU/ml, from 10 to 14 uIU/ml, or from 12 to 14uIU/ml. This increase in fasting serum insulin levels is concomitantwith or independent of the decrease in fasting glucose (FG)concentrations, and decrease in HbA1c discussed above for patientshaving HbA1c≥7.5.

As discussed in greater detail below one study's design, based on theHbA1c levels, divided participants into two categories: (1) G1, whichincluded participants with slightly elevated HbA1c levels (≤7.49%) andG2, comprised of participants with HbA1c levels above 7.5% (whichbasically is equivalent to glucose levels of 165 mg/dl or higher). TheHbA1c level of G1 corresponded in general to pre diabetics, milddiabetes or properly controlled diabetics (through oral medication).

As described below, one analysis performed was a Student t test forindependent samples in each of the diabetic categories and for each of 7variables (fasting glucose (FG), glycosylated hemoglobin (HbA1c),insulin, high density lipoprotein (HDL), low density lipoprotein (LDL),total cholesterol and triglycerides), comparing all participants whotook the example nutraceutical formulation of the present disclosure,regardless of dosage, with those who did not take the examplenutraceutical formulation (control treatment).

As illustrated in detail below, the bioactivity and nutraceuticalcharacteristics associated with the nutraceutical formulations disclosedand/or employed herein actively participate in the remediation of earlytype II diabetes, by actually lowering FG and HbA1c. The nutraceuticalformulations of the present disclosure also lower total cholesterol andLDL, thereby reducing the risks of cardiovascular disease associatedwith diabetes type II.

SUMMARY OF TEST AND RESULTS

A study with the objective of determining the impact of three doselevels of nutraceutical prepared in accordance with the currentdisclosure, taken twice daily over 3 months (90 days) on levels offasting glucose (FG), glycosylated hemoglobin (HbA1c), insulin, highdensity lipoprotein (HDL), low density lipoprotein (LDL), totalcholesterol and triglycerides in Type II hyperglycemic patients, wasconducted. Participants were divided into 2 diabetic categoriesdepending on HbA1c results: 40 adults with HbA1c<7.5% (G1) and 40diabetics with HbA1c≥7.5% (G2). Each category was further divided into 3nutraceutical dosage groups of 10 participants each, namely 5 g, 10 gand 15 g taken twice daily for a consumption period of 90 days. A zerocontrol treatment was also included.

Analysis of variance (ANOVA) showed significant decreases in fastingblood serum values for glucose, HbA1c, total cholesterol, tryglycerides,and low density lipoproteins in G1 participants. No significantdifferences were detected in the ANOVA of the G2 treatments. A treatment(dose) longitudinal analysis in the two categories showed that HbA1c andtotal cholesterol were significantly reduced by 11.4% and 18.2%,respectively, in the 15 gram G1 category. In the 15 gram treatment inthe G2 category, glucose was significantly reduced by 32.20%, from aninitial 263.89 mg/dl to 178.8 mg/dl after 90 days of twice daily intakeof 15 g of nutraceutical.

Student t test also showed that in the G2 category fasting insulinconcentration in the blood was significantly increased in a doseincremental fashion in all 3 nutraceutical treatments; the control groupshowed a minimal nonsignificant increase in insulin production,culminating with a statistically significant 1347.80% increase infasting insulin in the 15 gr dose. The longitudinal analysis of theG1/15 g nutraceutical treatment also showed that even thoughnon-significant, a −35.8% and −13.00% difference was detected in thetriglyceride and LDL levels by the end of the study.

These results show that the nutraceutical disclosed herein has thecapacity to substantially lower glucose, HbA1c, total cholesterol andLDL in diabetics, with a larger impact on people showing impairedglucose tolerance, characteristic of a pre-diabetic stage. In diabeticswith higher glucose levels and HbA1c values such as the G2 category,insulin production is significantly increased, from deficient secretionto normal values and glucose levels are significantly reduced.

Nutraceutical Formulation

The following studies were performed using a stabilized rice brannutraceutical derivative, with FDA-DSHEA compliance for humanconsumption. The nutraceutical formulations disclosed herein resulted,in part, from the combination of hydrophilic (soluble fraction) andlipophilic (fiber fraction) fractions extracted from stabilized ricebran as described in U.S. Pat. No. 8,945,642, which is hereinincorporated by reference in its entirety for all that it contains.

In one aspect, the methods disclosed herein use nutraceuticalformulations comprising nutritionally enhanced isolates of stabilizedrice bran having a soluble fraction/fiber fraction ratio of from 0.5 to1.5; 0.75 to 1.25; 1.0 to 1.5; 1.0 to 1.4; 1.0 to 1.3, 1.0 to 1.20; or1.0 to 1.15.

Blending and preparation of the finished nutraceutical formulation wasdone following the ingredient proportions shown below in Table 1. Toaccommodate varied taste preferences, the amount of vanilla was adjustedin some instances to 0.1%, while all other parameters in the formulationof Table 1 remained unchanged.

TABLE 1 Proportions of ingredients utilized in the formulation ofnutraceutical finished powdered beverage used in the hyperglycemicstudies described herein. lb. of finished product Ingredient % 1000 600Soluble Fraction 49.53 495.3 297.18 Fiber Fraction 42.97 429.7 257.82Customized Premix 3 30 18 Sweetener 2 20 12 CMC Gum 1.3 13 7.8 Vanilla1.2 12 7.2 TOTAL 100 1000 600

The customized premix used to prepare the finished nutraceutical formulais a vitamin and mineral premix comprising, per 6.7 grams of the premix:200 IU Vitamin D3 (as Cholecalciferol, USP-FCC); 30 IU Vitamin E (asacetate, USP-FCC); 90 mcg Biotin (USP); 6 mg Niacin (as Niacinamide,USP-FCC); 3 mg Pantothenic Acid (as D-Calcium Pantothenate, USP); 1.8mcg Vitamin B12 (as Cyanocobalamin, USP); 60 mg Vitamin C (as SodiumAscorbate, USP-FCC); 24 mcg Vitamin K1 (as Phytonadione, USP); 450 mg(Calcium (as Calcium Lactate, USP-FCC); 54 mcg Chromium (as ChromiumPicolinate, USP); 37.5 mcg Iodine (as Potassium Iodide, USP-FCC); 120 mgMagnesium (as Magnesium Phosphate, USP-FCC); 22.5 mcg Molybdenum (asSodium Molybdate); 350 mg Phosphorous (as Dipotassium Phosphate, anhy.,FCC) and (Magnesium Phosphate, FCC); 1050 mg Potassium (as DipotassiumPhosphate, anhy., FCC) and (Potassium Chloride, USP-FCC); 17.5 mcgSelenium (as Sodium Selenite); and 6 mg Zinc (as Zinc Sulfate, USP-FCC).

The study disclosed herein was designed as an open label research study,where both the researchers and the participants knew the dosage of thenutraceutical (from Table 1 above) that would be received twice daily,for a 90-day period.

The group invited to participate in the study was comprised of diagnosedor previously undiagnosed Type II hyperglycemic adult males or femalesolder than 30 years of age and younger than 65 years old. Oralmedication was accepted but not insulin dependent hyperglycemics.Fasting blood serum glucose levels ≥105 mg/dl were also required forinclusion in the study, as well as overall good health as determined by(1) the consulting physician's health assessment, (2) normal urinechemistry results, and (3) normal kidney and liver function. The bloodand urine chemistry methods can be seen in Table 2 below. All blood andurine chemistry was determined using a Merck Microlab 200 chemistryanalyzer (Kenilworth, N.J.) while insulin was determined using aRayto/RT-2100c microplate reader (Shenzhen, P.R. China).

TABLE 2 Methods applied in blood and urine chemistry analysis during theinitial medical health screening and later blood testing. VARIABLEMETHOD MANUFACTURER Insulin Accubind ELISA microwells Monobind Inc.,Lake Forest, CA Glucose Trinder, GOD-POD Spinreact Girona, Spain HbA1cQuantitative colorimetric StanBio Laboratory, Stanbio glycohemoglobnBoerne, TX procedure No. P350 Colesterol Spinreact CHOP-POD SpinreactGirona, enzymatic/colorimetric Spain HDL Spinreact HDL-P SpinreactGirona, Spain LDL Total cholesterol-HDL Triglycerides GPO-POD enzymatic/Spinreact Girona, colorimetric Spain TGO (liver) GOT (AST)-LQ SpinreactGirona, Spain TGP (liver) GPT (ALT)-LQ Spinreact Girona, SpainCreatinine Creatinine J Spinreact Girona, (kidley) Spain Urine chemistryUrinalysis Reagent Strips Spinreact Girona, Spain

Experimental Design

The experimental design, as shown in Table 3 below, was a 2×4 factorialarrangement where participants were divided into two hyperglycemiccategories based on HbA1c results: Group I (G1), comprised of 40hyperglycemics with HbA1c≤7.49% and Group 2 (G2) which included 40diabetics with HbA1c≥7.5%.

Each category group was further divided into 4 treatments, each with 10participants and consisting of 3 nutraceutical (from Table 1 above)dosages (5 g, 10 g and 15 g) in addition to one control treatment. Sincethe study contemplated two daily rations, participants consumed either10 g, 20 g or 30 g daily of the nutraceutical described in Table 1,depending on the treatment placement.

TABLE 3 Arrangement of 8 treatments in the 4 × 2 factorial design forthe nutraceutical hyperglycemic study in Guatemala. Each treatment wasinitially comprised of 10 participants for a total of 80 Type IIhyperglycemics. Factor A - Nutraceutical dose (twice daily) Factor B -HbA1c range 0 g 5 g 10 g 15 g 6.1%-7.49% (Group 1) G1, 0 G1, 5 G1, 10G1, 15 ≥7.5% (Group 2) G2, 0 G2, 5 G2, 10 G2, 15

Consumption of the nutraceutical, which was formulated and packaged inindividual sachets, occurred over a three month time period.

Blood Sampling and Testing

Following the initial base line blood testing shown in Table 2, twosubsequent blood testing were taken from participants at 45 days intothe consumption window and at 90 days (at the end of the nutraceuticalintervention period). Blood chemistry variables at the 45 and 90benchmark included the glucose-related variables fasting glucose, HbA1cand fasting insulin. Lipid-related variables included total cholesterol,low density lipoprotein, high density lipoprotein and triglycerides.

Results Selection of Participants

The results of diabetes screening events are shown in Table 4.

TABLE 4 Summary of results for hyperglycemic detection events. TotalPre-Prandial Total Pre-Prandial Total Number of hyperglicemcs slightlyhyperglycemics normal FG Participants (FG > 120) (FG 100-120) (<100) 3715 10 12 43 18 13 12 27 8 3 16 20 3 1 16 44 9 6 29 22 14 1 7 193 67 3492

In addition to the 193 detections test conducted, 22 more potentialparticipants were also screened for a total 215 fasting and postprandial glucose tests. Following the administration of glucose tests,potential participants were selected based on the fasting (≥105 mg/dl)and post-prandial blood glucose (≥140 mg/dl) results, as well as otherparameters including age, willingness to participate, known healthrisks, insulin dependency and Body mass index (BMI).

Of 215 potential participants, 122 were invited to assist with aninitial baseline screening, which included fasting blood chemistry andurine chemistry as well as medical clinical evaluations. Theseevaluations took place 3 or 4 times a week over approximately a 4 weekperiod. A total of 122 potential participants were evaluated and 81participants were finally selected to be in the study (Table 5).

TABLE 5 Final group of selected participants for nutraceutical (fromTable 1)/hyperglycemics study. Number of selected Number of screenedparticipants, based on lab potential participants results and medicalcheck up 13 9 9 6 15 10 14 12 13 9 10 5 15 11 6 5 18 10 9 5 122 82

Of the 82 screened potential candidates, 81 were divided into twocategories according to their HbA1c results: 40 participants withglycosylated hemoglobin (percentage of glycated hemoglobin in the blood)between 6.1% and 7.49% (labeled group G1) and 41 participants with HbA1cresults >7.5%, labeled group G2.

The hyperglycemic women in category G1 averaged 54.14±8.29 years of agewith an average BMI of 29.87±9.69, while men and 138.7 (±28.5) FG; 70%of participants were female. In contrast, hyperglycemics in category G2showed an average of 9.31% (±1.27%) HbA1c, 258 mg/dl (±52.4) FG andaveraged 52.1 years of age; 68% of participants were female.

Once the two main hyperglycemic groups were conformed, participants ineach main group were randomly assigned to 1 of 4 nutraceutical dosegroup (treatments—T—) as follows: TI, 0 grams (control group); T2: 5grams twice a day; T3: 10 grams twice a day; and T4: 15 grams twice aday, all as mid-morning and mid-afternoon snacks. The mean bloodchemistry results for each diabetic group can be seen in Table 6, whilethe age and body mass index (BMI) information is found in Table 7.

TABLE 6 Mean (±standard deviation -SD-) blood chemistry results fordiabetic groups G1 and G2. DIABETIC F.GLUC HbA1C TGO TGP Tot. Col. HDLLDL TRIG CREAT INSULIN GROUP MEAN/SD mg/dl (%) UI/L UI/L Mg/dl mg/dlmg/dl md/dl mg/dl uIU/ml G1 MEAN 138.7 6.71% 38.7 30.2 205.6 56.5 108.2206.7 0.8 7 SD 28.47 0.38% 12.88 10.08 49.98 11.28 34.01 119.7 0.18 7.07G2 MEAN 258.6 9.31% 34.2 27.8 209.7 57.3 106 256.3 0.9 2.3 SC 52.451.27% 8.24 10.23 44.68 10.47 30.44 183.9 0.24 3.09 F.GLUC: FG; HA1c:glycosylated hemoglobin; TGO: aspartate aminotransferase; TGP: alanineaminotransferase; Tot. Col: total cholesterol; HDL: highly densitylipoprotein; LDL: low density lipoprotein; TRK 3: triglycerides; CREAT:creatinin.

TABLE 7 Mean age and body mass index of women and men participating indiabetic groups G1 and G2. DIABETIC WOMEN MEN GROUP n age BMI n age BMIG1 28 53.97 ± 7.93 31.26 ± 5.42 10 57.25 ± 5.55 24.96 ± 3.00 G2 28 58.18± 9.29 26.77 ± 4.09 13 52.38 ± 8.16 24.88 ± 3.24

Analysis

The analysis of results has been structured as follows:

-   -   1. Summary of descriptive statistics: An exploratory analysis of        the results was performed using the statistical software        INFOSTAT 2015p. In this descriptive procedure, descriptive        statistics for each of the parameters (variables) obtained in        the initial, midterm and final blood sampling are presented.    -   2. Comparison of dependent variables in nutraceutical dosage        treatments: This analysis was performed using a Student T test        for independent samples applied to two populations. The first        population comprised all participants that took the        nutraceutical and the second population included those who did        not take the nutraceutical nutritional supplement. The purpose        of this analysis was to explore in a general qualitative sense        the effect of the nutraceutical on the dependent variables,        without discriminating between dosages.    -   3. Analysis of Variance (ANOVA) for comparison of dependent        variables between treatments: An ANOVA for a completely        randomized design was performed on each of the two diabetic        groups, G1 and G2, applying the following model:

Y _(i) =μ+T _(i)+ϵ_(i)

-   -   -   where Y_(i)=Response associated to the experimental unit;            μ=global mean; T_(i)=effect of the i-th dose of the            nutraceutical; ϵ=experimental error associated to the i-th            experimental unit.

    -   4. Longitudinal analysis for “before and after” effect of the        nutraceutical among participants: A Student t test for paired        data was applied to all 7 dependent variables obtained for the        initial and final blood sample of participants. This analysis        was run with the objective of determining G1f there had been any        statistically significant effects on the 3 diabetes related        factors and the 4 lipid-associated parameters before the        participants started consuming the nutraceutical and at the end        of the 90 day window.

    -   5. Descriptive analysis of “before and after” normal range        values of the 7 dependent variables among participants in the        two diabetic groups and 4 treatments.

1. Summary of Descriptive Statistics

As shown in Table 8, by the end of the study, the G1 control groupexhibited an increase of 22.78 mg/dl in the mean FG, while the 15 g doseparticipants lowered in average their FG by 7.1 mg/dl. Fasting glucosein participants in the 5 g and 10 g remained practically unchanged.Regarding G2 participants, while the control group showed a slightreduction (5%) of FG by the end of the trial, the nutraceuticaltreatments showed an increased effectiveness for lowering FG as thenutraceutical dosage increased, culminating with a 32% FG decrease inthe 15 g treatment.

TABLE 8 Summary of descriptive statistics for the variable Glucose-GLUC- (mg/dl) according to date of blood testing. Date 1 (0 days) Date2 (45 days) Date 3 (90 days) Group Treatment n Mean SD CV Mean SD CVMean SD CV G1 15 g 9 134.8 31.8 23.59 128.4 23.77 18.51 127.1 35.7728.14 10 g 7 126.96 18.05 14.22 104.71 23.64 22.57 129.67 52.96 40.84  5g 7 143.86 27.11 18.85 182.71 74.37 40.7 145.41 56.46 38.83 Control 11142.49 34.65 24.32 181.05 58.09 32.09 165.27 94.01 56.88 G2 15 g 7263.89 23.83 9.03 216.36 113.01 52.23 178.84 87.53 48.94 10 g 8 267.0555.96 20.95 261.61 85.61 32.72 213.39 62.89 29.47  5 g 9 248.35 36.1114.51 221.98 60.71 27.35 228.96 81.79 35.72 Control 7 227.9 43.72 19.19226.04 108.49 48 217.54 72 33.1G1 refers to diabetics with HbA1c>6.1 and ≤7.49; G2 included diabeticswith HbA1c≥7.50; Treatment refers to the dose of the nutraceutical takentwice daily. Control refers to the group of participants not taking thenutraceutical. SD=standard deviation of the mean and CV=coefficient ofvariation.

Similar to FG, the G1 HbA1 control group exhibited by the end of theconsumption window, an increase in the mean HbA1c (0.35 percentagepoints). In contrast, the 15 g dose participants lowered in averagetheir HbA1c by 0.77% (Table 9). This is a qualitative, clinicallysignificant result because while a 6.74% HbA1c is diagnosed as diabetes,a 5.97% HbA1c result is categorized as prediabetes, and very close tothe 5.7 upper limit normal result. HbA1c in the G1 5 g and 10 gparticipants was s lightly reduced by 0.24% and 0.33%, respectively. Itis noteworthy to mention that in both the 5 g and 10 g G1 groups, themean initial HbA1c value was above the threshold for a diabeticdiagnosis but by the end of the 90 day consumption period, the meanvalue in the 10 9 group was lowered to a pre-diabetic condition.

TABLE 9 Summary of descriptive statistics for the dependent variableGlycosylated Hemoglobin -HbA1c- (%) according to date of blood testing.Date 1 (0 days) Date 2 (45 days) Date 3 (90 days) Group Treatment n MeanSD CV Mean SD CV Mean SD CV G1 15 g 9 6.74 0.41 6.11 6.21 0.31 5.06 5.970.51 8.59 10 g 7 6.6 0.42 6.32 6.07 0.65 10.65 6.27 0.99 15.79  5 g 76.8 0.35 5.19 7 0.75 10.76 6.56 1.17 17.85 Control 11 6.68 0.45 6.677.23 1.23 17.06 7.03 1.7 24.23 G2 15 g 7 9.41 0.62 6.57 8.9 1.6 18.027.94 1.95 24.52 10 g 8 9.45 1.23 12.97 9.33 1.7 18.2 8.7 1.39 15.97  5 g9 9.14 1.09 11.88 8.64 1.18 13.66 8.61 1.62 18.82 Control 7 8.62 0.9911.55 8.55 1.77 20.74 8.33 1.51 18.18

Fasting serum insulin was the third diabetes-related dependent variable.As Table 10 shows, G1 participants had a higher basal levels of insulincompared to the G2 diabetics. In G1, including with normal insulinproduction baseline results, (between 5.99 μUI/ml and 8.35 μUI/ml) therewas an increase in insulin production in all three nutraceuticaltreatments. The control participants also showed slightly higher levelsof insulin at the end of the study. The nutraceutical group ofparticipants in G2 (HbA1c's≥7.5) showed a substantial increase ininsulin production. As Table 10 shows, while the G2 control participantsslightly increased their fasting serum insulin from 4.13 μUI/ml to 5.96μUI/ml, there was a marked incremental response in the nutraceuticaldoses, with fasting serum insulin increasing from 0.92 μUI/ml to 13.32μUI/ml in the 15 g treatment.

TABLE 10 Summary of descriptive statistics for the dependent variableinsulin (μUI/ml) according to date of blood testing. Date 1 (0 days)Date 2 (45 days) Date 3 (90 days) Group Treatment n Mean SD CV Mean SDCV Mean SD CV G1 15 g 9 8.31 7.40 89.09 8.27 6.08 73.47 12.17 7.33 60.2110 g 7 8.35 11.82 141.4 8.09 10.1 124.9 9.16 4.19 45.71  5 g 7 7.7 7.2694.35 5.43 5.31 97.82 25.93 42.19 162.6 Control 11 5.99 5.7 95.11 5.184.46 86.12 8.67 4.84 55.89 G2 15 g 7 0.92 1.14 123.1 2.52 2.52 100.113.32 10.66 80.03 10 g 8 2.22 1.84 83.13 3.69 2.28 61.83 8.23 2.79 33.85 5 g 9 2 2.25 112 1.97 2.14 109.1 5.94 4.08 68.71 Control 7 4.13 4 96.675.35 3.31 61.96 5.96 5.68 95.24

The lipid related dependent variables also showed decreasedconcentrations at the end of the nutraceutical consumption window, eventhough values were not excessively high in the participants at thebeginning of the trial. For example, total cholesterol (Table 11) waslowered by 19%, in the G1 15 g treatment, from 2 17.3 mg/dl to 177.7mg/dl. In the G2 group, there was a slight decrease in all treatmentsranging from 2.42% in the 15 g treatment to 6.67% in the 10 g treatment.

TABLE 11 Summary of descriptive statistics for the dependent variableTotal Cholesterol (mg/dl) according to date of blood testing. Date 1 (0days) Date 3 (45 days) Date 3 (90 days) Group Treatment n Mean SD CVMean SD CV Mean SD CV G1 15 g 9 217.3 46.37 21.34 174.14 42.87 24.62177.7 35.09 19.74 10 g 7 190.3 35.5 18.65 177.07 27.2 15.36 183.13 38.2220.87  5 g 7 174.13 59.2 34 171.34 52.37 30.57 165.04 46.82 28.37Control 11 214.45 47 21.92 203.68 53.43 26.23 187.02 34.52 18.46 G2 15 g7 207.73 41.47 19.96 169.16 25.54 15.1 202.41 28.79 14.23 10 g 8 217.4131.28 14.39 204.81 34.51 16.85 202.89 25.79 12.71  5 g 9 191.97 38.9120.27 186.62 40.31 21.6 184.32 46.59 25.27 Control 7 205.26 58.13 28.32209.63 49.04 23.39 195.16 43.68 22.38

High density lipoproteins (Table 12) showed an improvement in the 15 g,G2 participants, where HDL was increased from a mean value of 55.93mg/dl (n=7) to 58.16 mg/dl, an increase equivalent to 4% HDL. The restof the treatments in both G1 and G2 showed decreases in HDL values atthe final blood testing.

TABLE 12 Summary of descriptive statistics for the dependent variableHigh Density Lipoproteins -HDL- (mg/dl) according to date of bloodtesting. Date 1 (0 days) Date 2 (45 days) Date 3 (90 days) GroupTreatment n Mean SD CV Mean SD CV Mean SD CV G1 15 g 9 58.31 9.51 16.3150.02 13.47 26.93 52.47 10.73 20.44 10 g 7 51.94 10.09 19.42 49.89 6.6113.25 49.64 6.93 13.95  5 g 7 51.34 15.9 30.97 51.07 15.72 30.78 47.6610.18 21.36 Control 11 60.24 9.56 15.88 57.52 16.8 29.2 53.81 9.32 17.33G2 15 g 7 55.93 11.98 21.43 46.24 6.57 14.2 58.16 8.13 13.97 10 g 858.25 6.86 11.77 54.59 9.33 17.1 54.18 4.91 9.06  5 g 9 53.71 11.2720.99 53.06 12.59 23.74 50.58 11.16 22.06 Control 7 56.89 11.22 19.7257.4 11.7 20.39 55.86 10.74 19.22

Regarding LDL (Table 13), participants in all 8 treatments exhibitedinitially mean levels within the normal range of 70-170 mg/dl. In the G2group, while the control treatment participants exhibited a −4.20% meanLDL difference between the initial an final testing, the 10 gnutraceutical treatment group showed a reduction of 15.11%, from aninitial 116.79 mg/dl to a final 99.14 mg/dl of blood LDL.

TABLE 13 Summary of descriptive statistics for the dependent variableLow Density Lipoproteins -LDL- (mg/dl) according to date of bloodtesting. Date 1 (0 days) Date 2 (45 days) Date 3 (90 days) GroupTreatment n Mean SD CV Mean SD CV Mean SD CV G1 15 g 9 105.06 31.4529.93 86.1 23.76 27.59 91.34 14.96 16.38 10 g 7 91.27 27.01 29.6 75.8121.54 28.42 90.43 23.13 25.58  5 g 7 95.69 34.77 36.33 88.31 17.78 20.1380.2 15.56 19.4 Control 11 120.49 32.87 27.28 100.15 28.76 28.72 101.7531.08 30.55 G2 15 g 7 104.06 29.46 28.31 85.19 13.68 16.06 106.21 27.4125.81 10 g 8 116.79 21.97 18.81 99.61 20.23 20.31 99.14 11.84 11.95 5 g9 97.37 35.65 36.62 95.72 30.29 31.64 95.09 36.14 38 Control 7 101.8732.61 32.01 105.14 39.79 37.84 97.59 28.89 29.6

Triglycerides was the fourth lipid-related blood factor included in theblood tests. As Table 14 shows, there was a decrease in triglyceridelevels in both G1 and G2 groups at the I5 g nutraceutical dosage but the35% reduction in the G1 15 g treatment (from 291.13 mg/dl to 186.9mg/dl) was substantial, particularly when contrasted with the G1 controlgroup (which exhibited a 7% improvement).

TABLE 14 Summary of descriptive statistics for the dependent variableTriglycerides -TRIGS- (mg/dl) according to date of blood testing. Date 1(0 days) Date 2 (45 days) Date 3 (90 days) Group Treatment n Mean SD CVMean SD CV Mean SD CV G1 15 g 9 291.13 205.26 70.5 189.02 105.15 55186.9 111.9 59.87 10 g 7 219.3 50.82 23.17 324.97 160.4 49.35 215.9685.81 39.74  5 g 7 135.43 68.67 50.7 167.56 102.6 61.22 189.36 166.387.84 Control 11 174.37 62.4 35.79 218.46 88.36 40.45 162.23 69.68 42.95G2 15 g 7 240.83 125.3 52.03 189.27 53.98 28.52 222.46 167.1 75.1 10 g 8212.16 36.66 17.28 256.71 99.32 38.69 247.24 110.8 44.82  5 g 9 226.89133.7 58.95 189.91 74.77 39.37 238.22 160.6 67.4 Control 7 285.83 272.895.43 261.71 82.89 31.67 248.37 168.1 67.58

2. Comparison of Dependent Variables in the Nutraceutical DosageTreatments Versus the Control Treatment

This test was conducted with the objective of determining the overalleffect of the nutraceutical on the diabetes and lipid related bloodindicators, contrasting the results of those who took the nutraceuticalsupplement with the participants in the control treatment. This testgrouped all the results of those who took the nutraceutical and comparedthem to the means of all the results obtained from those who did nottake the nutraceutical (n=33). Table 15 shows the comparison for theoverall effects of the nutraceutical for the G1+nutraceutical (N=69) incontrast to the mean of all results obtained from blood tests onindividuals who did not take nutraceutical (N=33). Of the sevendependent variables, all three glucose-related parameters showedstatistically significant differences between the two groups. The lipidrelated parameters total cholesterol and LDL also showed significanteffects, with reduced levels in the +nutraceutical group in contrast tothe control treatment group. Table 16 shows the same comparison of+nutraceutical (N=72) blood results vs. no nutraceutical blood testresults (N=21) for participants in the G2 category, where no significantdifferences were detected between the overall means of the 7 dependentvariables. However a substantial reduction of −40.42 mg/dl was observedin the triglyceride levels of the blood tests of those who took thenutraceutical in comparison to those who did not take the supplement.

TABLE 15 Overall effect of the nutraceutical consumption between bloodtest results of those who took the nutraceutical compared toparticipants who did not consume the nutraceutical supplement (controltreatment) in G1 participants. No Plus Nutra- Nutra- Difference P-Variable ceutical ceutical In Means Value Test GLUC (mg/dl) 135.45162.94 −27.49 0.0360 *− HbA1c (%) 6.45 6.98 −0.53 0.0265 *− COL. TOT(mg/dl) 181.88 201.72 −19.84 0.0366 *+ HDL (mg/dl) 51.57 57.19 −5.620.0233 *+ LDL (mg/dl) 89.78 107.46 −17.69 0.0023 *+ TRIG (mg/dl) 214.08185.02 29.06 0.1658 NS− INSULIN (uUI/ml) 10.31 6.61 3.7 0.0740 NS−

TABLE 16 Overall effect of the nutraceutical consumption between bloodtest results of those who took the nutraceutical compared toparticipants who did not consume the nutraceutical supplement (controltreatment) in G2 participants. No Plus Nutra- Nutra- Difference P-Variable ceutical ceutical In Means Value Test GLUC (mg/dl) 234 223.8310.17 0.5759 NS+ HbA1c (%) 8.9 8.5 0.41 0.2457 NS+ COL. TOT (mg/dl)196.14 203.35 −7.21 0.4632 NS+ HDL (mg/dl) 53.81 56.71 −2.9 0.2427 NS+LDL (mg/dl) 99.81 101.53 −1.73 0.8047 NS+ TRIG (mg/dl) 224.89 265.3−40.42 0.3433 NS− INSULIN (uUI/ml) 4.44 5.15 −0.71 0.5780 NS+

3. Analysis of Variance (Anova) 3.1 Kruskal-Wallis Anova

A nonparametric Kruskal-Wallis ANOVA was applied using the statisticalpackage INFOSTAT. As Table 17 shows, in the G1 significant differenceswere found in the diabetes related variables FG and HbA1c. In the lipidrelated variables significant differences were found in TotalCholesterol, LDL and Triglycerides. No significant differences werefound in HDL or Insulin. With regards to the G2 group, no significantdifferences were found between treatments in any of the 7 testedvariables (Table 18).

TABLE 17 Non-parametric analysis of variance results for blood testvariables in the group of G1 participants with HbA1c ≥6.1 and ≤7.49%.VARIABLE P-VALUE GLUCOSE (mg/dl) 0.0067 * HbA1c (%) 0.0375 * TOTALCOLESTEROL (mg/dl) 0.0403 * HDL (mg/dl) 0.0625 NS LDL (mg/dl) 0.0127 *TRIGLYCERIDES (mg/dl) 0.0121 * INSULIN (uUI/ml) 0.4371 NS Asteriskdenotes statistically significant differences (p ≤ 0.05) detected in atleast one of the treatments.

TABLE 18 Non-parametric analysis of variance results for blood testvariables in the group of G2 participants with HbA1c ≥7.5%. VARIABLEP-VALUE GLUCOSE (mg/dl) 0.5511 NS HbA1c (%) 0.3557 NS TOTAL COLESTEROL(mg/dl) 0.3185 NS HDL (mg/dl) 0.6044 NS LDL (mg/dl) 0.5512 NSTRIGLYCERIDES (mg/dl) 0.4314 NS INSULIN (uUI/ml) 0.2284 NS Asteriskdenotes statistically significant differences (p ≤ 0.05) detected in atleast one of the treatments, while NS refers to statisticallynon-significant differences.

3.2 A Posteriori Mean Comparison Tests for Variables ShowingStatistically Significant Differences (A=95%) According to the KruskalWallis Non-Parametric Anova.

FIGS. 1A-1E show a posteriori mean comparison tests for variablesshowing statistically significant differences (p≤0.05) betweentreatments in the G1 group of participants, according to theKruskal-Wallis non parametric ANOVA. As FIGS. 1A-1E show, the variablesglucose, HbA1c, total cholesterol and LDL all showed significantreductions in their fasting levels, with the control treatment in adiscrete category all of its own. The most significant reductions weregenerally found in the 15 g and 10 g treatments, even though the 5 gtreatment also showed marked improvements in total cholesterol and LDL.

4. Longitudinal Analysis for “Before and After” Effect of NutraceuticalAmong Participants

With the exception of HDL, all dependent variables in the G1-15 gtreatment showed a favorable response on the longitudinal analysis asdetermined by the Student t test for paired data (Table 19). In theglucose-related variables, HbA1c exhibited a statistically significant11.40% reduction, while FG was reduced by 5.70%. Insulin levels wereincreased by 46.50% but were non-significant. Regarding thelipid-related variables, total cholesterol was significantly reduced by18.20% (p<0.05) and LDL by 13.00%. Triglycerides were reduced by 35.80%having started at 291.13 mg/dl and ended at 186.9 mg/dl. The reason forthe triglyceride results being non-significant (even though substantial)may lie on the fact that the data was too disperse and did not follow anormal distribution, according to the statistical software INFOSTAT.

TABLE 19 Student t test results for comparison of “before and after”mean blood test results for 7 variables in each of the treatments of theG1 group of participants. Mean Treatment Variable N Initial FinalDifference¹ p-value 15 g GLUC 9 134.8 127.1  −5.70% 0.6474 NS mg/dlHbA1c 9 6.74 5.97 −11.40% 0.0173 * (%) INSULIN 9 8.31 12.17   46.50%0.2578 NS uUI/ml COLTOT 9 217.3 177.7 −18.20% 0.0088 * (mg/dl) HDL 958.31 52.47 −10.00% 0.0702 NS (mg/dl) LDL 9 105.06 91.34 −13.00% 0.2039NS (mg/dl) TRIG 9 291.13 186.9 −35.80% 0.2058 NS (mg/dl) 10 g GLUC 7126.96 129.67    2.10% 0.8898 NS mg/dl HbA1c 7 6.6 6.27  −5.00% 0.4516NS (%) INSULIN 7 8.35 9.16    9.60% 0.8261 NS uUI/ml COLTOT 7 190.3183.13  −3.80% 0.6251 NS (mg/d) HDL 7 51.94 49.64  −4.40% 0.5618 NS(mg/dl) LDL 7 91.27 90.43  −0.90% 0.9365 NS (mg/dl) TRIG 7 219.3 215.96 −1.50% 0.9229 NS (mg/dl)  5 g GLUC 7 143.86 145.41    1.10% 0.9531 NSmg/dl HbA1c 7 6.8 6.56  −3.40% 0.6464 NS (%) INSULIN 7 7.7 6.44−16.36    0.2989 NS uUI/ml COLTOT 7 174.13 165.04  −5.20% 0.5702 NS(mg/dl) HDL 7 51.34 47.66  −7.20% 0.3995 NS (mg/dl) LDL 7 95.69 80.2−16.20% 0.2004 NS (mg/dl) TRIG 7 135.43 189.36   39.80% 0.2679 NS(mg/dl) Control GLUC 11 142.49 165.27   16.00% 0.3799 NS mg/dl HbA1c 116.68 7.03    5.20% 0.4438 NS (%) INSULIN 11 5.99 8.67   44.70% 0.2859 NSuUI/ml COLTOT 11 214.45 187.02 −12.80% 0.1204 NS (mg/dl) HDL 11 60.2453.81 −10.70% 0.1229 NS (mg/dl) LDL 11 120.49 101.75 −15.60% 0.1377 NS(mg/dl) TRIG 11 174.37 162.23  −7.00% 0.5761 NS (mg/dl)

In the G2 diabetic group longitudinal analysis (Table 20), theirresulted a significant increase in insulin levels in all 3 nutraceuticaltreatments in contrast to the control group which was not statisticallysignificant (p=0.1552). The greatest increase was observed in the 15 G1nsulin levels with a final fasting G1nsulin concentration of 13.32μIU/ml after having started at the below normal basal level of 0.92μIU/ml), an indicator for an almost non-existent insulin production bythe pancreas. The FG levels were also significantly reduced (P<0.05) inthe G2-15 g treatment but the HbA1c levels, even though substantial at−15.60% were not found to be significant. HDL levels were increased by4%, while the rest of treatments showed reductions in the final HDLvalues. In the nutraceutical treatments total cholesterol was reducedbetween 2 0.6% and 6.7% and LDL between 2. 10% and 15.10% (10 gnutraceutical).

TABLE 20 Student t test results for comparison of “before and after”mean blood test results for 7 variables in each of the treatments of theG2 group of participants. Mean Treatment Variable N Initial FinalDifference¹ p-value 15 g GLUC mg/dl 7 263.89 178.84 −32.20% 0.0311 *HbA1c (%) 7 9.41 7.94 −15.60% 0.0613 NS INSULIN (uUI/ml) 7 0.92 13.321347.80% 0.0189 * COL. TOT (mg/dl) 7 207.73 202.41 −2.60% 0.7687 NS HDL(mg/dl) 7 55.93 58.16 4.00% 0.6412 NS LDL (mg/dl) 7 104.06 106.21 2.10%0.7637 NS TRIG (mg/dl) 7 240.83 222.46 −7.60% 0.7924 NS 10 g GLUC mg/dl8 287.05 213.39 −20.10% 0.0831 NS HbA1c (%) 8 9.45 8.7 −7.90% 0.1228 NSINSULIN (uUI/ml) 8 2.22 8.23 270.70% 0.0021 * COL. TOT (mg/dl) 8 217.41202.89 −6.70% 0.0602 NS HDL (mg/dl) 8 58.25 54.18 −7.00% 0.1203 NS LDL(mg/dl) 8 116.79 99.14 −15.10% 0.0413 * TRIG (mg/dl) 8 212.16 247.2416.50% 0.3505 NS  5 g GLUC mg/dl 9 248.83 228.96 −8.00% 0.453 NS HbA1c(%) 9 9.14 8.61 −5.80% 0.3836 NS INSULIN (uUI/ml) 9 2 5.94 297.00%0.0224 * COL. TOT (mg/dl) 9 191.97 184.32 −4.00% 0.4096 NS HDL (mg/dl) 953.71 50.58 −5.80% 0.2882 NS LDL (mg/dl) 9 97.37 95.09 −2.30% 0.7846 NSTRIG (mg/dl) 9 226.89 238.22 5.00% 0.5871 NS Control GLUC mg/dl 7 227.9217.54 −4.50% 0.5703 NS HbA1c (%) 7 8.62 8.33 −3.40% 0.384 NS INSULIN(uUI/ml) 7 4.13 5.96 44.30% 0.1552 NS COL. TOT (mg/dl) 7 205.26 193.16−4.90% 0.2796 NS HDL (mg/dl) 7 56.89 55.86 −1.80% 0.3209 NS LDL (mg/dl)7 101.87 97.59 −4.20% 0.3324 NS TRIG (mg/dl) 7 285.83 248.37 −13.10%0.505 NS

5. Descriptive Analysis of “Before and After” Normal Range Values 5.1Prediabetic Group G1

The analysis of percentage of participants within ‘normal range values’for the 7 dependent is important from a clinical point of view. In thepre/mild/controlled diabetic group of participants not much of a changewas seen in the percentage of participants falling within normal FGvalues before and after the nutraceutical intervention in any of the 4dose treatments (FIG. 2 ).

In contrast, a significant change was detected in the number ofparticipants who fell in the normal range values for HbA1c at the end ofthe study, particularly in the 15 g treatment, as can be seen in FIG. 3.

With regards to insulin, many of the G1 participants were already in thenormal range at the beginning of the study. However in the treatment of10 g all participants were within the normal range of insulin at the endof the study, compared to 57% initially (FIG. 4 ).

With regards to total cholesterol, approximately half of theparticipants in treatments 10 g and 15 g were in the normal range at thebeginning of the study. By the end of the study, 86% and 78% of theparticipants in these two same treatments fell within the normal rangefor total cholesterol (FIG. 5 ).

In the case of HDL, no substantial change was found between the initialand final percentages within the normal range but, as FIG. 6 shows, themajority of participants were already within normal range at thebeginning of the study.

With regards to LDL many participants were also within normal range atthe start of the trial, but whereas there was a slight decrease in thepercentage of participants of the control group within normal values atthe end of the study, the three nutraceutical treatments showed a slightincrease in the number of participants falling in the normal range atthe same point in time (FIG. 7 ).

Finally, in the case of triglycerides (FIG. 8 ), increases in the numberof participants falling within normal values were higher in all threenutraceutical treatments compared to the control. However the greatestincrease was found in the 15 gram treatment, where the percentage ofparticipants showing triglyceride values within normal ranges increasedfrom 22.2% at the beginning of the study to 55.6% by the end of thetrial, an increase of 150%.

Overall, the most substantial increases in the proportion ofparticipants falling within normal range was observed in the variablesHbA1c, LDL and triglycerides in the 15 gr dose of the nutraceutical,while insulin and glucose showed the most improvement in the 10 gr dose(Table 21).

TABLE 21 Percentage of change in the proportion of participants fallingwithin normal range values at the end of the study in the pre-diabeticG1 group. GROUP 1 Percentange of Treatment Variable participants¹Control GLUC (mg/dl) 9.10% HbA1c (%) 27.30% INSULIN (uUI/ml) 36.40% COL.TOT (mg/dl) 36.40% HDL (mg/dl) 9.10% LDL (mg/dl) −9.10% TRIG (mg/dl)9.10%  5 g GLUC (mg/dl) 0.00% HbA1c (%) 42.99% INSULIN (uUI/ml) −14.30%COL. TOT (mg/dl) 14.30% HDL (mg/dl) 28.60% LDL (mg/dl) 14.30% TRIG(mg/dl) 0.00% 10 g GLUC (mg/dl) 14.30% HbA1c (%) 28.60% INSULIN (uUI/ml)42.90% COL. TOT (mg/dl) 28.60% HDL (mg/dl) 0.00% LDL (mg/dl) 14.30% TRIG(mg/dl) 14.30% 15 g GLUC (mg/dl) 11.10% HbA1c (%) 66.70% INSULIN(uUI/ml) 0.00% COL. TOT (mg/dl) 33.30% HDL (mg/dl) 0.00% LDL (mg/dl)11.10% TRIG (mg/dl) 33.30% ¹Percentange refers to the change (positiveor negative) in the proportion of participants falling within normalrange values by the end of the study.

Diabetic Group G2

Diabetic group 2 showed no participants falling within normal range forFG values at the beginning of the study. However, by the end of theintervention window, 28.6% of the participants in the 15 g nutraceuticaltreatment showed normal values for glucose (FIG. 9 ).

Similarly to FG, no participants fell with in normal values for HbA1C atthe beginning of the study in the G2 group. By the end of the trial,12.5% and 28.6% of participants exhibited normal glycosylated hemoglobinvalues in the 10 G and 15 g treatments, respectively (FIG. 10 ).

As can be seen in FIG. 11 , the majority of participants fell below thenormal insulin values at the beginning of the study. By the end of the 3month nutraceutical period however, 88.9%, 100% and 85 0.7% ofparticipants were categorized within the normal insulin range in the 5g, 10 g and 15 g nutraceutical treatments, respectively. In contrast,the proportion of participants within normal insulin values remained thesame in the control group.

With regards to the variable total cholesterol (FIG. 12 ) controlpercentages remained unchanged at the end of the study, but theproportion of participants falling within the normal value rangeincreased in all 3 nutraceutical groups with the greatest improvementseen in the 10 g and 15 g treatments.

In the case of HDL, no substantial change was found between the initialand final percentages of participants with in the normal range. This canbe explained by the fact that as FIG. 13 shows, the majority ofparticipants were already within normal range at the beginning of thestudy. Similar results were obtained with LDL's (FIG. 14 ), whiletriglycerides remained basically unchanged at the end of the study (FIG.15 ).

The most substantial change was observed in the variable insulin wherethe percentage of participants within normal range values increased inall three nutraceutical doses, while the control group remainedunchanged at 0% (Table 22).

TABLE 22 Percentage of change in the proportion of participants fallingwithin normal range values at the end of the study in the pre-diabeticG2 group. GROUP 2 Percentange of Treatment Variable participants¹Control GLUC (mg/dl) 0.00% HbA1c (%) 0.00% INSULIN (uUI/ml) 0.00% COL.TOT (mg/dl) 0.00% HDL (mg/dl) 14.30% LDL (mg/dl) 0.00% TRIG (mg/dl)0.00%  5 g GLUC (mg/dl) 0.00% HbA1c (%) 0.00% INSULIN (uUI/ml) 33.30%COL. TOT (mg/dl) 11.10% HDL (mg/dl) 11.10% LDL (mg/dl) −11.10% TRIG(mg/dl) −22.20% 10 g GLUC (mg/dl) 0.00% HbA1c (%) 12.50% INSULIN(uUI/ml) 75.00% COL. TOT (mg/dl) 37.50% HDL (mg/dl) 0.00% LDL (mg/dl)0.00% TRIG (mg/dl) 25.00% 15 g GLUC (mg/dl) 28.60% HbA1c (%) 28.60%INSULIN (uUI/ml) 71.40% COL. TOT (mg/dl) 14.30% HDL (mg/dl) 0.00% LDL(mg/dl) 0.00% TRIG (mg/dl) 0.00% ¹Percentange refers to the change(positive or negative) in the proportion of participants falling withinnormal range values by the end of the study.

The demonstrative nutraceutical of Table 1 demonstrated a significantcapacity for lowering the levels of all 3 diabetes-related bloodparameters. In the pre-diabetic (also known as impaired glucosetolerance) or mild diabetes category, 10 g and 15 g twice daily of thenutraceutical significantly decreased fasting glucose and HbA1c comparedto the control group (0 nutraceutical). In the longitudinal analysis,fasting serum insulin of the HbA1c>7.5% category was significantlygreater in all nutraceutical treatments, compared to the control group.

Overall prediabetics or mild diabetics had a better response to thenutraceutical compared to participants with HbA1c≥7.5%, with significantreductions in both glucose-related and lipid related blood variables.Significant reductions were found in Glucose, HbA1c, total cholesterol,and LDL in G1 participants taking the nutraceutical, compared to theparticipants in the control group.

Participants in the HbA1c≥7.5% category, exhibited a significantincrease in their fasting serum insulin level after base line insulinlevels at the beginning of the trial showed deficient insulinproduction. By the end of the study, participants in the G2 group hadnot only significantly lowered their fasting glucose levels but theirfasting serum insulin concentration had significantly increased, in adose-responsive fashion, evidence of increased biosynthesis.Participants in G1 group did not have a significant fastinG1nsulinincrease, however their fastinG1nsulin levels were within normal rangeat all times during the clinical trial.

As disclosed herein, nutraceutical prepared in accordance with thisdisclosure, and summarized in Table 1, were provided twice daily (e.g.,the 5 g dose is equivalent to 10 daily grams of the nutraceutical, the10 g treatment was equivalent to 20 daily grams, and the 15 g dose wasequivalent to 30 daily grams of nutraceutical). Table 23 below shows themean diabetes-related blood chemistry results between after 90 days ofconsumption of the example nutraceutical described in Table 1.

TABLE 23 FASTING GLUCOSE HbA1c(%) FASTING INSULIN mg/dl DifferenceuUI/ml Difference with control Difference with control Percent withcontrol Treatment average mg/dl % average points % average uIU/ml %GROUP 1 (HbA1c ≥ 6.1% & < 7.5) Control 165.27 7.03 8.67  5 gr 145.41−19.86 −12.02 6.56 −0.47 −6.69 6.44 −2.23 −25.72 10 gr 129.67 −35.60−21.54 6.27 −0.76 −10.81 9.16 0.49 5.65 15 gr 127.10 −38.17 −23.10 5.97−1.06 −15.08 12.17 3.50 40.37 GROUP 2 (HbA1c ≥ 7.5) Control 217.54 8.335.69  5 gr 228.96 11.42 8.61 0.28 5.94 0.25 4.39 10 gr 213.39 −4.15−1.91 8.70 0.37 4.44 8.23 2.29 44.64 15 gr 178.84 −38.70 −17.79 7.94−0.39 −4.68 13.32 7.63 123.49Values in italics are statistically significant (p<0.05) from valuesobtained in the control treatment.

Table 24 below shows the longitudinal comparison of the before (0 days)and after (90 days) diabetes-related blood chemistry results atfinalization of the nutraceutical consumption period.

TABLE 24 FASTING GLUCOSE HbA1c(%) FASTING INSULIN mg/dl DifferenceuUI/ml Difference with control Difference with control Percent withcontrol Treatment average mg/dl % average points % average uIU/ml %GROUP 1 (HbA1c ≥ 6.1% & < 7.5) Control 0 days 142.49 6.68 5.99 90 days165.27 22.78 15.99 7.03 0.35 5.24 8.67 2.68 44.74 5 grams 0 days 143.866.80 7.70 90 days 145.41 1.55 1.08 6.56 −0.24 −3.53 6.44 −1.26 −16.36 10grams 0 days 126.96 6.60 8.35 90 days 129.67 2.71 2.13 6.27 −0.33 −5.009.16 0.81 9.70 15 grams 0 days 1.34 6.74 8.13 90 days 127.1 −7.70 −5.715.97 −0.77 −11.42 12.17 3.86 46.45 GROUP 2 (HbA1c ≥ 7.5) Control 0 days227.9 8.62 4.13 90 days 217.54 −10.36 −4.55 8.33 −0.29 −3.36 5.96 1.8344.31 5 grams 0 days 248.82 9.14 2.00 90 days 228.96 −19.86 −7.98 8.61−0.53 −5.80 5.94 3.94 197.00 10 grams 0 days 267.05 9.45 2.22 90 days213.39 −53.66 −20.09 8.70 −0.75 −7.94 8.23 6.01 270.72 15 grams 0 days263.89 9.41 0.92 90 days 178.84 −85.05 −32.23 7.94 −1.47 −15.62 13.3212.40 1347.83Values in italics are statistically significant (p<0.05) from valuesobtained in the control treatment.

Clearly, the nutraceuticals disclosed herein are an effective tool formanagement of blood glucose as part of a comprehensive integratedstrategy for diabetes management, particularly for those affected byimpaired glucose tolerance (pre-diabetes).

1. A method of managing chronic health conditions related to type IIdiabetes, said method comprising the administration of a nutraceuticalin an amount sufficient to decrease HbA1c blood concentrations in typeII diabetic patients, said stabilized rice bran extract nutraceuticalcomprising a hydrophilic soluble fraction/lipophilic fiber fractionratio of about 1.0 to about 1.5.
 2. A method of managing chronic healthconditions related to type II diabetes, said method comprising theadministration of a nutraceutical in an amount sufficient to reduce thefasting glucose concentration in blood, said stabilized rice branextract nutraceutical comprising a hydrophilic solublefraction/lipophilic fiber fraction ratio of about 1.0 to about 1.5.
 3. Amethod of managing chronic health conditions related to type IIdiabetes, said method comprising the administration of a nutraceuticalin an amount sufficient to increase the serum fasting insulin levels,said stabilized rice bran extract nutraceutical comprising a hydrophilicsoluble fraction/lipophilic fiber fraction ratio of about 1.0 to about1.5.